ClinicalTrials.gg
Not yet recruitingNCT07745894Updated Oct 28, 2026

VWCR to Improve Cardiovascular Health and Outcomes Among Cardiac Patients: A Multicenter Randomized Clinical Trial Protocol (Destination Cardiac Rehab Study)

An interventional study of Virtual Cardiac Rehabilitation and In-Person Cardiac Rehabilitation in Heart Diseases, sponsored by Mayo Clinic. Not yet recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Health services research

How we know

Updated Oct 28, 2026Start date movedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 22 studies in Heart Diseases by Mayo Clinic — 3 open to participants now, 4 under way, none of them phase 3. Heart Diseases · Mayo Clinic.

Started
2026
with 1 other
No phase
5 of 22
2 open now
Registered
22nd of 22
by date

Among the 22 studies in Heart Diseases by Mayo Clinic, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 22nd registered.

Heart Diseases

2,135 studies on the registry are indexed under Heart Diseases; 250 are open to participants now.

Browse Heart Diseases studies →

Open to participants now

3 of the 22 studies in Heart Diseases by Mayo Clinic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 182 Heart Diseases studies recruiting now, 128 (70%) set no upper age limit and 22 (12%) stop at 75 or younger; 33 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Heart Diseases by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to compare health outcomes and participation between a virtual world cardiac rehabilitation (Destination Cardiac Rehab) program and the standard of care Center-based Cardiac Rehabilitation program. Destination Cardiac Rehab, developed with input from patients with heart disease and their caregivers, is a 3-D, interactive program offering an affordable telehealth option for cardiac rehabilitation (cardiac rehab) that can be done from home or any place that you can access the Internet with a computer.

03

Conditions studied

  • Heart Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Indication for CR according to Centers for Medicare \& Medicaid Services (CMS) guidelines:

    • Myocardial infarction within the preceding 12 months
    • Coronary artery bypass surgery
    • Current stable angina (chest pain)
    • Heart valve repair or replacement
    • Percutaneous transluminal coronary angioplasty (PTCA) or coronary stenting
    • Heart or heart-lung transplant
    • Stable chronic heart failure
  • Aged ≥18 years
  • Basic Internet navigation skills
  • Active email address

Exclusion criteria

Exclusion Criteria:

  • High risk patients according to the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR) risk stratification103 given safety concern of unsupervised exercise:

    • Sudden cardiac arrest survivor
    • Receiving continuous inotropic support
    • Presence of a mechanical circulatory support device
    • Decompensated heart failure
    • Symptomatic valvular heart disease
    • Uncontrolled angina
    • Presence of hemodynamically unstable dysrhythmias (e.g., ventricular tachycardia)
  • Pregnant (due to associated hormonal and weight changes)
  • Non-English-speaking
  • Visual/hearing impairment or mental disability that would preclude independent use of the VW platform
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    Virtual World-based Cardiac Rehabilitation

    Other: Virtual Cardiac Rehabilitation

  • Active comparator
    Control Arm

    Other: In-Person Cardiac Rehabilitation

Interventions

  • OtherVirtual Cardiac Rehabilitation

    * Weekly Virtual Cardiac Rehabilitation Session * Virtual Nurse Coaching Visit (frequency: weekly) * Virtual Exercise Physiologist Visit (frequency: weekly) * Self-Directed Exercise: 3 sessions per week

  • OtherIn-Person Cardiac Rehabilitation

    Participants will attend three in-person cardiac rehabilitation sessions per week, each including: * Supervised exercise under the guidance of an Exercise Physiologist * Educational components related to cardiac health and lifestyle

06

What researchers measure

Primary outcomes

  1. Change in LE8 composite score

    Life's Essential 8 score is a composite cardiovascular health (CVH) score developed by the American Heart Association (AHA) to quantify and track an individual's heart- and brain-health based on eight key lifestyle behaviors and clinical health factors (healthy diet, physical activity, nicotine exposure, sleep health, body mass index, lipids, glucose and blood pressure). The score ranges from 0 to 100 points, with higher scores indicating better overall cardiovascular health. Interpretation of the composite score usually follows these general categories: 0-49: Low cardiovascular health 50-79: Moderate cardiovascular health 80-100: High (optimal) cardiovascular health

    Time frame: Baseline, 3 Months, 6 Months

Secondary outcomes

  1. Number of CV-related hospital readmissions

    Number of CV-related hospital readmissions will be defined as the total number of participants readmitted to the hospital for a cardiovascular-related issue.

    Time frame: 3 Months, 6 Months

  2. Number of Deaths

    Number of deaths will be defined as the total number of participants who die, regardless of cause

    Time frame: 3 Months, 6 Months

  3. Number of CV Deaths

    Number of CV deaths will be defined as the total number of participants who die due to cardiovascular (CV)-related causes.

    Time frame: 3 Months, 6 Months

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2029, 33 months later.

Of 264 non-industry interventional studies with no phase under Heart Diseases, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 33 months is above that.

Counting every sponsor, half of 337 studies reached it within 25 months; a quarter within 11 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Aug 2026 → Nov 2026, primary completion Aug 2028 → Aug 2029 and completion Aug 2028 → Aug 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2026
First posted
Aug 4, 2026
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Aug 2029was Aug 2028
CompletionEst.
Aug 2029was Aug 2028
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 2026→Nov 2026
Oct 28, 2026
Primary completion
Aug 2028→Aug 2029
Oct 28, 2026
Study completion
Aug 2028→Aug 2029
Oct 28, 2026
Contact
Study contact changed: •••7062→o•••@mayo.edu. See the current contact
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Start date Aug 2026→Nov 2026
    Primary completion Aug 2028→Aug 2029
    Study completion Aug 2028→Aug 2029
    Contact Study contact changed: •••7062→o•••@mayo.edu. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07745894
Lead sponsor
Mayo Clinic
Responsible party
LaPrincess C. Brewer (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 4, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 2029 (estimated)
Completion
Aug 2029 (estimated)
Last update
Oct 28, 2026

Study contacts

Ashton Krogman
Contact
krogman.ashton@mayo.edu
507-266-2087
Kolawole Olarinoye
Contact
olarinoye.kolawole@mayo.edu
LaPrincess Brewer, MD, MPH
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion